JOMPAC
Journal of Medicine and Palliative Care

Journal of Medicine and Palliative Care (JOMPAC) is an open access scientific journal with independent, unbiased, and double-blind review under international guidelines. The purpose of JOMPAC is to contribute to the literature by publishing articles on health sciences and medicine.

eISSN: 2717-7505
Creative Commons CC BY-NC-ND 4.0 International License.
EndNote Style

Submit Manuscript

Index
Original Article
The effect of maximum tumor diameter and 18F-FDG PET/CT imaging status on overall survival in Hodgkin lymphoma patients
Abstract
Aims: This research aims to determine the impact of maximum tumor diameter and FDG PET CT status at the time of diagnosis on survival outcomes and to identify prognostic factors that influence treatment response and survival.
Methods: 239 patients with a diagnosis of Hodgkin lymphoma participated in the study. Clinical characteristics, treatment responses, and prognostic factors influencing survival were retrospectively analyzed from patient medical records.
Results: There were 136 (56.9%) male patients and 103 (43.1%) female patients, who participated in the study. Of these patients, 202 (84.5%) survived, while 37 (15.5%) died during the study period. When surviving patients and non-survivor patients were compared, the deceased patients had a higher mean age (p=0.003), a higher prevalence of spleen involvement and B symptoms (p=0.011 and p=0.001, respectively), lower albumin levels (p=0.008), higher beta-2 microglobulin levels (p=0.001), and more bone marrow involvement (p=0.006). A fourfold increase in mortality was seen in patients with beta-2 microglobulin levels >2920 mg/L, and a 3.188-fold increase in mortality was seen in patients with spleen involvement.
Conclusion: In conclusion, beta-2 microglobulin >2920 mg/L, the presence of spleen involvement, the presence of relapse, and the presence of progressive or refractory disease in FDG PET CT were significant prognostic factors for 1st, 3rd, and 5th-year survival rates in patients with Hodgkin lymphoma. In addition, there was no correlation between survival rate and maximum tumor diameter as measured by FDG-PET or CT.

Keywords : Hodgkin lymphoma, clinical indicators, prognostic factors, FDG PET CT

Download Article


1. Belsky JA, Hochberg J, Giulino-Roth L. Diagnosis andmanagement of Hodgkin lymphoma in children, adolescents, andyoung adults. Best Pract Res Clin Haematol. 2023;36(1):101445.
2. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022.CA Cancer J Clin. 2022;72(1):7-33. doi:10.3322/caac.21708
3. Hanel W, Herrera AF, Epperla N. Management of classicalHodgkin lymphoma: a look at up to date evidence and currenttreatment approaches. Exp Hematol Oncol. 2022;11(1):108.
4. Follows AM, Santarsieri A. Minimising the toxicities of firstline Hodgkin lymphoma treatment in the modern era. Cancers(Basel). 2022;14(21):5390.
5. Barrington SF, Phillips EH, Counsell N, et al. Positron emissiontomography score has greater prognostic significance thanpretreatment risk stratification in early-stage Hodgkin Lymphomain the UK RAPID study. J Clin Oncol. 2019;37(20):1732-1741.
6. Borchmann P, Plütschow A, Kobe C, et al. PET-guided omissionof radiotherapy in early-stage unfavourable Hodgkin lymphoma(GHSG HD17): a multicentre, open-label, randomised, phase 3trial. Lancet Oncol. 2021;22(2):223-234.
7. Borchmann P, Goergen H, Kobe C, et al. PET-guided treatmentin patients with advanced-stage Hodgkin’s lymphoma (HD18):final results of an open-label, international, randomisedphase 3 trial by the German Hodgkin Study Group. Lancet.2017;390(10114):2790-2802.
8. Kharazmi E, Fallah M, Pukkala E, et al. Risk of familial classicalHodgkin lymphoma by relationship, histology, age, and sex: ajoint study from five Nordic countries. Blood. 2015;126(17):1990-1995.
9. Daw S, Hasenclever D, Mascarin M, et al. Risk and responseadapted treatment guidelines for managing first relapsed andrefractory classical Hodgkin lymphoma in children and youngpeople. recommendations from the EuroNet Pediatric HodgkinLymphoma Group. Hemasphere. 2020;4(1):e329.
10. Illidge TM, Phillips EH, Counsell N, et al. Maximum tumordiameter is associated with event-free survival in PET-negativepatients with stage I/IIA Hodgkin lymphoma. Blood Adv.2020;4(1):203-206.
11. Moskowitz AJ, Schöder H, Gavane S, et al. Prognostic significanceof baseline metabolic tumor volume in relapsed and refractoryHodgkin lymphoma. Blood. 2017;130(20):2196-2203.
12. Dores GM, Curtis RE, Dalal NH, Linet MS, Morton LM. Cause-specific mortality following initial chemotherapy in a population-based cohort of patients with classical Hodgkin lymphoma, 2000-2016. J Clin Oncol. 2020;38(35):4149-4162.
13. Follows GA, Barrington SF, Bhuller KS, et al. Guideline for thefirst-line management of Classical Hodgkin Lymphoma-ABritish Society for Haematology guideline. Br J Haematol.2022;197(5):558-572.
14. Goodlad JR, Cerroni L, Swerdlow SH. Recent advances incutaneous lymphoma-implications for current and futureclassifications. Virchows Arch. 2023;482(1):281-298.
15. de Jong PA, van Ufford HM, Baarslag HJ, et al. CT and 18F-FDGPET for noninvasive detection of splenic involvement inpatients with malignant lymphoma. AJR Am J Roentgenol.2009;192(3):745-53.
16. Rueffer U, Sieber M, Josting A, et al. Prognostic factorsfor subdiaphragmatic involvement in clinical stage I-IIsupradiaphragmatic Hodgkin’s disease: a retrospective analysis ofthe GHSG. Ann Oncol. 1999;10(11):1343-8.
17. Noordijk EM, Carde P, Dupouy N, et al. Combined-modalitytherapy for clinical stage I or II Hodgkin’s lymphoma: long-termresults of the European Organisation for Research and Treatmentof Cancer H7 randomized controlled trials. J Clin Oncol.2006;24(19):3128-35.
18. Engert A, Plütschow A, Eich HT, et al. Reduced treatmentintensity in patients with early-stage Hodgkin’s lymphoma. NEngl J Med. 2010;363(7):640-52.
19. Eatrides J, Thompson Z, Lee JH, Bello C, Dalia S. Serum albuminas a stable predictor of prognosis during initial treatment inpatients with diffuse large B cell lymphoma. Ann Hematol.2015;94(2):357-358.
20. Gradel KO, Larsen TS, Frederiksen H, et al. Impact of C-reactiveprotein and albumin levels on short, medium, and long termmortality in patients with diffuse large B-cell lymphoma. AnnMed. 2022;54(1):713-722.
21. Al-Ibraheem A, Mottaghy FM, Juweid ME. PET/CT in Hodgkinlymphoma: an update. Semin Nucl Med. 2023;53(3):303-319.
22. Juweid ME, Mueller M, Alhouri A, MZ AR, Mottaghy FM.Positron emission tomography/computed tomography in themanagement of Hodgkin and B-cell non-Hodgkin lymphoma: anupdate. Cancer. 2021;127(20):3727-3741.
23. Cashen AF, Dehdashti F, Luo J, Homb A, Siegel BA, BartlettNL. 18F-FDG PET/CT for early response assessment in diffuselarge B-cell lymphoma: poor predictive value of internationalharmonization project interpretation. J Nucl Med. 2011;52(3):386-392.
Article available in :
Volume 4, Issue 5, 2023
Page : 485-491
https://doi.org/10.47582/jompac.1350661
Article Information
Received : 27 Ağu 2023
Accepted : 25 Eyl 2023
Published : 27 Eki 2023
Corresponding Author :

Vildan Terzioğlu: Department of Hematology, Bursa City Hospital, Bursa, Turkey

[email protected]
Citation : Gürsoy V, Göktuğ MR, Hunutlu FÇ, et al. The effect of maximum tumor diameter and 18F-FDG PET/CT imaging status on overall survival in Hodgkin lymphoma patients. J Med Palliat Care. 2023;4(5):485-491.

Read: -25
Cited: 0
Download : 141
_Footer